Current Rheumatology Reports

, Volume 10, Issue 4, pp 297–302 | Cite as

Remission in psoriatic arthritis

  • Kurt de VlamEmail author
  • Rik J. U. Lories


Psoriatic arthritis (PsA) is a chronic inflammatory joint disease associated with psoriasis that can lead to joint deformity and disability. PsA has a low likelihood of clinical remission and cure. For a long time, therapeutic options for PsA patients have been unsatisfactory, but the introduction of anti-tumor necrosis factor agents have markedly improved articular and cutaneous signs and symptoms. The efficacy of tumor necrosis factor blockers also raised the bar for treatment goals in PsA. Remission may now be an attainable outcome in the treatment paradigm. At this time, specific tools to define PsA remission are not available. New assessments to define remission must be developed and incorporated into clinical trials and longitudinal registries.


Rheumatoid Arthritis Psoriasis Etanercept Rheumatol Psoriatic Arthritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Khan M, Schentag C, Gladman DD: Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol 2003, 30: 1022–1026.PubMedGoogle Scholar
  2. 2.
    Sokoll KB, Helliwell PS: Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001, 28: 1842–1846.PubMedGoogle Scholar
  3. 3.
    Gladman DD: Natural history of psoriatic arthritis. Baillieres Clin Rheumatol 1994, 8: 379–394.PubMedCrossRefGoogle Scholar
  4. 4.
    Husted J, Gladman DD, Long JA, Farewell VT: Relationship of the Arthritis Impact Measurement Scales to changes in articular status and functional performance in patients with psoriatic arthritis. J Rheumatol 1996, 23: 1932–1937.PubMedGoogle Scholar
  5. 5.
    Gladman DD, Hing EN, Schentag CT, Cook RJ: Remission in psoriatic arthritis. J Rheumatol 2001, 28: 1045–1048.PubMedGoogle Scholar
  6. 6.
    Mease PJ, Goffe BS, Metz J, et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 29: 385–390.CrossRefGoogle Scholar
  7. 7.
    Antoni CE, Kavanaugh A, Kirkham B, et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52: 1227–1236.PubMedCrossRefGoogle Scholar
  8. 8.
    de Vlam K, Lories RJ: Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology 2006, 45: 321–324.PubMedCrossRefGoogle Scholar
  9. 9.
    Gladman DD, Mease PJ, Ritchlin CT, et al.: Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007, 56: 476–488.PubMedCrossRefGoogle Scholar
  10. 10.
    Kavanaugh A, Krueger GG, Beutler A, et al.; IMPACT 2 Study Group: Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007, 66: 498–505.PubMedCrossRefGoogle Scholar
  11. 11.
    Kavanaugh A, Fransen J: Defining remission in psoriatic arthritis. Clin Exp Rheumatol 2006, 24(6 Suppl 43): S83–87.Google Scholar
  12. 12.
    Pinals RS, Masi AT, Larsen RA: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981, 24: 1308–1315.PubMedCrossRefGoogle Scholar
  13. 13.
    Mierau M, Schoels M, Gonda G, et al.: Assessing remission in clinical practice. Rheumatology 2007, 46: 975–979.PubMedCrossRefGoogle Scholar
  14. 14.
    van der Helm-van Mil AH, Breedveld FC, Huizinga TW: Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activity. Arthritis Res Ther 2006, 8: 216–222.PubMedCrossRefGoogle Scholar
  15. 15.
    Lichtenstein MJ, Pincus T: Rheumatoid arthritis identified in population based cross sectional studies: low prevalence of rheumatoid factor. J Rheumatol 1991, 18: 989–993.PubMedGoogle Scholar
  16. 16.
    Harrison BJ, Silman AJ, Barrett EM, et al.: Presence of psoriasis does not influence the presentation or short-term outcome of patients with early inflammatory polyarthritis. J Rheumatol 1997, 24: 1744–1749.PubMedGoogle Scholar
  17. 17.
    Tunn EJ, Bacon PA: Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993, 32: 97–103.PubMedCrossRefGoogle Scholar
  18. 18.
    van Aken J, van Dongen H, le Cessie S, et al.: Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study. Ann Rheum Dis 2006, 65: 20–25.PubMedCrossRefGoogle Scholar
  19. 19.
    Kane D, Stafford L, Bresnihan B, FitzGerald O: A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003, 42: 1460–1468.CrossRefGoogle Scholar
  20. 20.
    Morgan C, Lunt M, Bunn D, et al.: Five-year outcome of a primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis. Rheumatology (Oxford) 2007, 46: 1819–1823.CrossRefGoogle Scholar
  21. 21.
    Lindqvist UR, Alenius GM, Husmark T, et al.: The Swedish early psoriatic arthritis register—2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008, 35: 668–673.PubMedGoogle Scholar
  22. 22.
    Fransen J, Antoni C, Mease PJ, et al.: Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006, 65: 1373–1378.PubMedCrossRefGoogle Scholar
  23. 23.
    Kaltwasser JP, Nash P, Gladman D, et al.; Treatment of Psoriatic Arthritis Study Group: Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004, 50: 1939–1950.PubMedCrossRefGoogle Scholar
  24. 24.
    Lories RJ, Derese I, Luyten FP, de Vlam K: Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment. Clin Exp Rheumatol 2008, 26: 96–102.PubMedGoogle Scholar
  25. 25.
    Vander Cruyssen B, De Keyser F, Kruithof E, et al.: Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo. Ann Rheum Dis 2007, 66: 138–140.CrossRefGoogle Scholar
  26. 26.
    Husted JA, Gladman DD, Farewell WT, Cook RJ: Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001, 45: 151–158.PubMedCrossRefGoogle Scholar
  27. 27.
    Krueger G, Koo J, Lebwohl M, et al.: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001, 137: 280–284.PubMedGoogle Scholar
  28. 28.
    Leeb BF, Andel I, Sautner J, et al.: The Disease Activity Score in 28 joints in RA and psoriatic arthritis patients. Arthritis Rheum 2007, 57: 256–260.PubMedCrossRefGoogle Scholar
  29. 29.
    Gladman DD, Inman RD, Cook RJ, et al.: International spondyloarthritis interobserver reliability exercise—the INSPIRE study: I. Assessment of spinal measures. J Rheumatol 2007, 34: 1733–1739.PubMedGoogle Scholar
  30. 30.
    Gladman DD, Inman RD, Cook RJ, et al.: International spondyloarthritis interobserver reliability exercise—the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007, 34: 1740–1745.PubMedGoogle Scholar
  31. 31.
    de Vlam K, Lories RJ, Janssen S: Remission is an achievable goal in the treatment of psoriatic arthritis. Ann Rheum Dis 2007, 66(Suppl2): 415–416.Google Scholar
  32. 32.
    Elkayam O, Yaron I, Shirazi I, et al.: Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. Rheumatol Int 2000, 19: 101–105.PubMedCrossRefGoogle Scholar
  33. 33.
    Foell D, Kane D, Bresnihan B, et al.: Expression of the proinflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology 2003, 42: 1383–1389.PubMedCrossRefGoogle Scholar
  34. 34.
    Gratacós J, Casado E, Real J, Torre-Alonso JC: Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 2007, 66: 493–497.PubMedCrossRefGoogle Scholar
  35. 35.
    Mastroianni A, Minutilli E, Mussi A, et al.: Cytokine pro-files during infliximab monotherapy in psoriatic arthritis. Br J Dermatol 2005, 153: 531–536.PubMedCrossRefGoogle Scholar
  36. 36.
    Ribbens C, Martin y Porras M, Franchimont N, et al.: Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002, 61: 161–166.PubMedCrossRefGoogle Scholar
  37. 37.
    Cordiali-Fei P, Trento E, D’Agosto G, et al.: Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann N Y Acad Sci 2007, 1110: 578–589.PubMedCrossRefGoogle Scholar
  38. 38.
    Levene AP, Morgan GJ, Davies FE: The use of genetic microarray analysis to classify and predict prognosis in haematological malignancies. Clin Lab Haematol 2003, 25: 209–220.PubMedCrossRefGoogle Scholar
  39. 39.
    Luyten FP, Lories RJ, Verschueren P, et al.: Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract Res Clin Rheumatol 2006, 20: 829–848.PubMedCrossRefGoogle Scholar
  40. 40.
    de Vlam K, Lories RJ, Luyten FP: Mechanisms of pathologic new bone formation. Curr Rheumatol Rep 2006, 8: 332–337.PubMedCrossRefGoogle Scholar
  41. 41.
    Wang JH, Li Z, Yang G, Khan M: Repetitively stretched tendon fibroblasts produce inflammatory mediators. Clin Orthop Relat Res 2004, (422): 243–250.PubMedCrossRefGoogle Scholar
  42. 42.
    de Vlam K, Gottlieb AB, FitzGerald O: A review of biological biomarkers in psoriatic disease (GRAPPA 2007). J Rheumatol 2008 (in press).Google Scholar
  43. 43.
    de Vlam K, Lories RJ, Janssen S: Prediction of time relapse after withdrawal of etanercept in psoriatic arthritis. Ann Rheum Dis 2007, 66(Suppl 2): 416.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Division of RheumatologyUniversity Hospitals LeuvenLeuvenBelgium

Personalised recommendations